Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

TOP 1703: Osimertinib for Patients with Stage 4 Non-Small Cell Lung Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to look at if the study drug, osimertinib, is safe and will work on patients with non-small cell lung cancer (NSCLC).
What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults who have confirmed non-small cell lung cancer with EGFR Mutations

Age Group

What is Involved?

If you choose to join this study, you will:
-Take Osimbertinib (80mg) by mouth
- Have routine eye exams and EKGs
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have unbearable side effects

Study Details

Full Title
A Single-Arm Phase II Study Osimertinib in Patients with Stage 4 Non-small Cell Lung Cancer with Uncommon EGFR Mutations
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00088376
NCT: NCT03434418
Phase II
Contact the Duke Recruitment Innovation Center